“There could have been more granularity on which specific groups should go get a booster,” Dr. Jonathan Watanabe, a professor of clinical pharmacy and dean at the University of California, Irvine, told Forbes in an email. “There is definitely room for interpretation, both by clinicians and patients,” as to whether someone’s condition compromises their immune system as much as ACIP’s reference of transplant patients, he said. Being more specific would also be useful for vaccine clinics and pharmacies, to know who is eligible.
CDC committee approves third Covid-19 shot for immunocompromised people—here’s who should get one
Forbes, Aug. 13, 2021
August 13, 2021